Get the Stockscreener App
3.14
1.26%
-0.04
Alumis Inc stock is traded at $3.14, with a volume of 637.16K.
It is down -1.26% in the last 24 hours and down -29.60% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$3.18
Open:
$3.17
24h Volume:
637.16K
Relative Volume:
0.64
Market Cap:
$369.79M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1171
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-12.53%
1M Performance:
-29.60%
6M Performance:
-62.57%
1Y Performance:
+0.00%
1-Day Range:
$3.10
$3.2685
1-Week Range:
$3.10
$3.70
52-Week Range:
$3.10
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
3.14 | 369.79M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
(ALMS) Trading Advice - news.stocktradersdaily.com
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Guggenheim - Defense World
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday - Defense World
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com India
Traders Purchase High Volume of Put Options on Alumis (NASDAQ:ALMS) - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
Alumis to Present at the Jefferies Global Healthcare Investor Conference - The Manila Times
AyurMaya Capital Management's Strategic Acquisition in Alumis Inc - GuruFocus
Alumis CEO to Share Late-Stage Immune Disease Pipeline Updates at Jefferies Healthcare Conference - Stock Titan
News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts - simplywall.st
Alumis completes enrollment of Phase 3 ONWARD program of ESK-001 - TipRanks
Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis - Nasdaq
Alumis Advances Game-Changing Oral Psoriasis Drug: 1,700 Patients Enrolled in Phase 3 Trial - Stock Titan
Largest borrow rate increases among liquid names - TipRanks
FY2026 Earnings Forecast for Alumis Issued By HC Wainwright - Defense World
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
How To Trade (ALMS) - news.stocktradersdaily.com
Alumis Inc. Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating - marketscreener.com
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (ALMS) ALUMIS INC. Reports Q1 Revenue $17.4M - marketscreener.com
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
ACELYRIN-Alumis Merger Gets Green Light: New Powerhouse in Immune Disease Treatment Emerges - Stock Titan
Barclays PLC Has $193,000 Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Mariner LLC Buys Shares of 18,122 Alumis Inc. (NASDAQ:ALMS) - Defense World
(ALMS) On The My Stocks Page - news.stocktradersdaily.com
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):